Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 8, 2004, Pages 1492-1497

  Liu, Ming Lin ^a,d   Ylitalo, Kati ^a   Salonen, Riitta ^b   Salonen, Jukka T ^b,c   Taskinen, Marja Riitta ^a,e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c Inner Savo Health Centre   (Finland)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Biomedicum Helsinki ^*  (Finland)

Author keywords

Carotid arteries; Familial combined; Hyperlipoproteinemia; Lipoproteins; Low denisty lipoprotein; Oxygen radical; Ultrasonography

Indexed keywords

8 ISOPROSTANE; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; ISOPROSTANE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; URATE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CONTROLLED STUDY; DISEASE MARKER; FAMILIAL HYPERLIPEMIA; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; IN VITRO STUDY; INTIMA; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTIVARIATE ANALYSIS; PARTICLE SIZE; PRIORITY JOURNAL; TUNICA MEDIA; URIC ACID BLOOD LEVEL;

ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; DINOPROST; DISEASE SUSCEPTIBILITY; FEMALE; FINLAND; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; PARTICLE SIZE; TUNICA INTIMA; TUNICA MEDIA;

EID: 3943057543     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000135982.60383.48     Document Type: Article

References (49)

1. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
2. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-1654.
3. Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation. 2001;103:1930-1932.
4. Avogaro P, Bon GB, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 1988;8:79-87.
5. Sevanian A, Bittolo-Bon G, Cazzolato G, Hodis H, Hwang J, Zamburlini A, Maiorino M, Ursini F. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997;38:419-428.
6. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18: 100-107.
7. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996;37:45-53.
8. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, Witztum JL. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103:117-128.
9. Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjala K, Pasanen P, Neuvonen K, Raitakari O, Viikari J. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis. 2001;155:403-412.
10. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844-848.
11. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1560.
12. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, Witztum JL, Frostegard J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104: 1887-1893.
13. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002;22:1162-1167.
14. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet. 1973;1:954-959.
15. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
16. Ludwig PW, Hunninghake DB, Hoidal JR. Increased leucocyte oxidative metabolism in hyperlipoproteinaemia. Lancet. 1982;2:348-350.
17. Pronai L, Hiramatsu K, Saigusa Y, Nakazawa H. Low superoxide scavenging activity associated with enhanced superoxide generation by monocytes from male hypertriglyceridemia with and without diabetes. Atherosclerosis. 1991;90:39-47.
18. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98: 2822-2828.
19. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230-3235.
20. Liu ML, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenpera S, Viikari J, Taskinen MR. Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Ann Med. 2002;34:48-54.
21. Vakkilainen J, Jauhiainen M, Ylitalo K, Nuotio IO, Viikari JS, Ehnholm C, Taskinen MR. LDL particle size in familial combined hyperlipidemia. Effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res. 2002;43:598-603.
22. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87:II56-II65.
23. Porkka KV, Nuotio I, Pajukanta P, Ehnholm C, Suurinkeroinen L, Syvanne M, Lehtimaki T, Lahdenkari AT, Lahdenpera S, Ylitalo K, Antikainen M, Perola M, Raitakari OT, Kovanen P, Viikari JS, Peltonen L, Taskinen MR. Phenotype expression in familial combined hyperlipidemia. Atherosclerosis. 1997;133:245-253.
24. Vartiainen E, Puska P, Jousilahti P, Korhonen HJ, Tuomilehto J, Nissinen A. Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. Int J Epidemiol. 1994;23:495-504.
25. Porkka KV, Viikari JS, Ronnemaa T, Marniemi J, Akerblom HK. Age and gender specific serum lipid and apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns Study. Acta Paediatr. 1994;83:838-848.
26. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke. 2002;33:1255-1260.
27. Liu ML, Bergholm R, Makimattila S, Lahdenpera S, Valkonen M, Hilden H, Yki-Jarvinen H, Taskinen MR. A marathon run increases the susceptibility of LDL to oxidation in vitro and modifies plasma antioxidants. Am J Physiol. 1999;276:E1083-1091.
28. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis. 1988;8:168-177.
29. Upston JM, Terentis AC, Morris K, Keaney Jr JF, Stocker R. Oxidized lipid accumulates in the presence of α-tocopherol in atherosclerosis. Biochem J. 2002;363:753-760.
30. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen SP. α-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002;106:1453-1459.
31. Wen Y, Killalea S, Norris LA, Cooke T, Feely J. Vitamin E supplementation in hyperlipidaemic patients: effect of increasing doses on in vitro and in vivo low-density lipoprotein oxidation. Eur J Clin Invest. 1999; 29:1027-1034.
32. O'Byrne D, Devaraj S, Islam KN, Collazo R, McDonald L, Grundy S, Jialal I. Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism. 2001;50:207-115.
33. van Tits LJ, de Waart F, Hak-Lemmers HL, van Heijst P, de Graaf J, Demacker PN, Stalenhoef AF. Effects of α-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers. Free Radic Biol Med. 2001;30: 1122-1129.
34. Silaste ML, Rantala M, Alfthan G, Aro A, Witztum JL, Kesaniemi YA, Horkko S. R2 Changes in Dietary Fat Intake Alter Plasma Levels of Oxidized Low-Density Lipoprotein and Lipoprotein(a). Arierioscler Thromb Vasc Biol. 2004;22:22.
35. Holvoet P, Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 1998;137:S33-S38.
36. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
37. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1011-1017.
38. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002;22:662-666.
39. Jansen H, Ghanem H, Kuypers JH, Birkenhager JC. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis. 1995;115:255-262.
40. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
41. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kuhne H, Julius U, Graessler J. In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance. Diabetes. 2002;51:3102-3106.
42. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 2000;148:171-177.
43. Gopaul NK, Nourooz-Zadeh J, Mallet AI, Anggard EE. Formation of F2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett. 1994;348:297-300.
44. Salonen JT, Yla Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
45. Salonen JT, Nyyssonen K, Salonen R, Porkkala-Sarataho E, Tuomainen TP, Diczfalusy U, Bjorkhem I. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation. 1997;95:840-845.
46. Regnstrom J, Nilsson J, Tomvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183-1186.
47. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999;83: 1330-1333.
48. Moussavi N, Renier G, Roussin A, Mamputu JC, Buithieu J, Serri O. Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:69-77.
49. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B, Brunner H, Laurent S. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation. 2000;101:2601-2606.